/Investor DB

3E Bioventures Capital — 2024 Investments

1 investments dated 2024 · listed companies and verified rows first · show all

Myrobalan Therapeuticsmyrotx.cominSeries A · Jan 2024 · $24M

Myrobalan Therapeutics is a pre-clinical biotech company developing small molecule therapies targeting microglia and oligodendrocytes to address neurodegeneration and demyelinating disorders.

AI & Machine LearningBiotechDeep TechMedical DevicesBoston, US

Jing Wang, PhD(Co-Founder & CEO)Guoping Feng, PhD(Scientific Co-Founder)Zhigang He(Scientific Co-founder)Guoping Feng(Scientific Co-founder)Minmin Yang(Director)Jing Yu Wang(Executive Officer, Director)

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.